Huntingtons disease treatment advances

Recent advances in Huntington’s disease (HD) treatment include new symptomatic therapies and several experimental disease-modifying programs Verified Answer #1. While research into slowing disease progression is ongoing, most breakthrough therapies remain in the experimental stage Verified Answer #1.

Approved Symptomatic Treatments

The most significant recent advance in clinical practice is the approval of new treatments for chorea, which are involuntary movements associated with HD Verified Answer #1.

• Valbenazine (Ingrezza): This medication is a VMAT2 inhibitor used to reduce chorea Verified Answer #1.
• Approval Status: The FDA granted marketing approval for valbenazine for adults with HD-related chorea on August 18, 2023 Verified Answer #1.
• Limitations: Although valbenazine treats symptoms, it does not address the underlying disease process Verified Answer #1.

Experimental Disease-Modifying Therapies

Research is currently focused on disease-modifying candidates that aim to lower mutant huntingtin levels or slow the progression of the disease Verified Answer #1.

• AMT-130: This is considered the most advanced gene therapy candidate in regulatory terms for disease modification Verified Answer #1.
• Oral Candidates: Votoplam (formerly PTC518) and SKY-0515 are significant oral disease-modifying candidates currently under investigation Verified Answer #1.

Clinical Outlook and Challenges

There is currently no therapy approved by the FDA that has been proven to slow or halt the progression of Huntington’s disease Verified Answer #1. The field has faced recent challenges, including the failure of high-profile candidates such as tominersen and RG6496 Verified Answer #1. These failures underscore the continued uncertainty in developing effective disease-modifying treatments Verified Answer #1.